DRUG · Unmapped registry intervention
[225]-FPI-2059
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
NCT05605522
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
[111In]-FPI-2058
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)unresolved
Colorectal Cancerverified · MONDO: colorectal cancer
Gastric Cancerverified · MONDO: gastric cancer
Ewing Sarcomaverified · MONDO: Ewing sarcoma
NTSR1 Expressing Solid Tumoursunresolved
Interventions
[225]-FPI-2059DRUG
[111In]-FPI-2058DRUG
Sponsors & collaborators
3B Pharmaceuticals GmbHlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05605522 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.